Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alterity Therapeutics

Market Cap 78.57M 67.72M 62.33M 58.47M 110M 7.43B 111M 737M 288M 3.64B 295M 289M 12.58B P/E Ratio 2026 *
-0.2x
P/E Ratio 2027 * -0.2x
Enterprise Value 33.38M 28.77M 26.48M 24.84M 46.67M 3.16B 47.13M 313M 122M 1.55B 125M 123M 5.35B EV / Sales 2026 *
9.75x
EV / Sales 2027 * 23.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics

1 day+2.94%
1 week+12.90%
Current month+16.67%
1 month+5.00%
3 months+31.25%
6 months+31.25%
Current year+31.25%
1 week 0.45
Extreme 0.45
0.54
1 month 0.4
Extreme 0.4
0.54
Current year 0.35
Extreme 0.35
0.55
1 year 0.35
Extreme 0.35
0.85
3 years 0.1
Extreme 0.1
0.95
5 years 0.1
Extreme 0.1
2.1
10 years 0.1
Extreme 0.1
20.5
Manager TitleAgeSince
Chief Executive Officer 65 06/01/2021
Director of Finance/CFO - 29/09/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 28/07/2005
Director/Board Member 47 07/08/2011
Director/Board Member 65 20/11/2025
Date Insider Type Main position Quantity % Market Cap.
04-14Other

Chief Executive Officer

346,123,874 3.1826%
04-09Other

Director

32,424,243 0.2981%
04-09Other

Director

56,060,607 0.5155%

Financials

2026 *2027 *
Net sales 3.42M 2.95M 2.72M 2.55M 4.79M 324M 4.83M 32.12M 12.54M 158M 12.85M 12.58M 548M 1.6M 1.38M 1.27M 1.19M 2.24M 151M 2.26M 15.01M 5.86M 74.06M 6.01M 5.88M 256M
Net income -13.44M -11.59M -10.66M -10M -18.79M -1.27B -18.98M -126M -49.24M -622M -50.44M -49.38M -2.15B -22.29M -19.21M -17.68M -16.59M -31.16M -2.11B -31.47M -209M -81.65M -1.03B -83.65M -81.87M -3.57B
Net Debt -45.19M -38.95M -35.85M -33.63M -63.17M -4.27B -63.8M -424M -166M -2.09B -170M -166M -7.24B -40.88M -35.24M -32.43M -30.42M -57.15M -3.86B -57.72M -383M -150M -1.89B -153M -150M -6.55B
Logo Alterity Therapeutics
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Sector
-
Date Price Change Volume
16/06/26 0.5250 $ +2.94% 131,125
15/06/26 0.5100 $ +3.03% 304,013
12/06/26 0.4950 $ +6.45% 217,606
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5100AUD
Average target price
2.280AUD
Spread / Average Target
+347.06%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!